Search for predicvite factors of anti-PD-1 antibody, pembrolizumab

Search for predicvite factors of anti-PD-1 antibody, pembrolizumab - Search for predicvite factors of anti-PD-1 antibody, pembrolizumab

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000030284

Enrollment

100

Registered

2020-04-01

Start date

2017-06-30

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

advanced non-small cell lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Advanced non-small cell lung cancer who is treated with penbrolizumab, having measurable lesions according to Response Evaluation Criteria in Solid Tumors (RECIST) Ver 1.1 2)Aged 20 years or older at consent time. 3)With written informed consent.

Exclusion criteria

Exclusion criteria: 1)Positive HBS-ag and/or HCV-ab 2)Positive HIV-ab 3)the primary doctor judging inappropriate for entry

Design outcomes

Primary

Measure	Time frame
Detection of gelsolin immunocomplex	—

Secondary

Measure	Time frame
1) Response rate of pembrolizumab 2) Detection rate of Gelsolin immune complex 3) Progression free survival (PFS) of pembrolizumab 4) Number of immune complexes in serum of pembrolizumab administration cases 5) Number of Gelsolin immune complexes in serum of pembrolizumab administration cases	—

Countries

Japan

Contacts

Public ContactYoichi Nakamura

Tochigi Cancer Center Department of Medical Oncology, Division of Thoracic Oncology

yonakamu@tochigi-cc.jp0286585151

Outcome results